Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

Core Insights - Regeneron Pharmaceuticals is set to present 36 abstracts at the 2026 AAAAI Annual Meeting, highlighting new Phase 3 data for investigational allergen-blocking antibodies targeting cat and birch allergies, as well as new insights on Dupixent's efficacy across various diseases [1][2] Regeneron's Pipeline and Research - The company is pioneering first-in-class treatments for cat and birch allergies, with Phase 3 data demonstrating the potential to alleviate ocular symptoms in adults [2][3] - Additional registration-enabling trials for these allergy treatments are planned for this year, aiming to evaluate similar endpoints over longer follow-up periods [3] - Regeneron's broader allergy pipeline includes innovative strategies aimed at eliminating all IgE-mediated allergies [3] Dupixent Insights - New analyses on Dupixent will be presented, focusing on its impact on allergy sensitization in children with atopic dermatitis, measuring IgE levels for various allergens over a treatment period of up to 1.5 years [4] - Real-world analyses will assess the potential benefits of initiating Dupixent earlier in asthma treatment, comparing its effects on exacerbation rates and corticosteroid use against other treatment options [5] - Late-breaking data from the Phase 3 AIMS trial for allergic fungal rhinosinusitis (AFRS) will also be shared, which supports a supplemental Biologics License Application currently under Priority Review [6] Presentation Details - The full list of Regeneron's presentations at the AAAAI includes various studies on allergic inflammation, immunological evaluations, and the efficacy of antibody cocktails in treating allergic conditions [7][8]